Advertisement

Relationship Between Specialized Pro-resolving Mediators and Inflammatory Markers in Chronic Cardiac Disorders

  • M. Brianza-Padilla
  • R. Bojalil
Chapter
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 1161)

Abstract

The term cardiovascular diseases (CVD) refers to disorders of heart and blood vessels, and include coronary heart disease, cerebrovascular disease, peripheral vascular disease, and heart failure, among others. Atherosclerosis is a common background of these diseases. It is not infrequent that some acute diseases, such as coronary syndromes, appear superimposed on a chronic arterial disease. Acute coronary syndromes (ACS), found worldwide among the leading causes of death, can be the origin of disabling chronic CVD such as heart failure [46]. Clinical and experimental evidence associates this group of alterations with an inflammatory process that takes part in its pathophysiology. In fact, inflammation is one of the most important factors for its initiation, progression, and consolidation [6].

Keywords

Pro-resolving mediators Inflammation Cardiac disorders 

References

  1. 1.
    AbuMweis S, Jew S, Tayyem R, Agraib L (2018) Eicosapentaenoic acid and docosahexaenoic acid containing supplements modulate risk factors for cardiovascular disease: a meta-analysis of randomised placebo-control human clinical trials. J Hum Nutr Diet 31(1):67–84.  https://doi.org/10.1111/jhn.12493CrossRefPubMedGoogle Scholar
  2. 2.
    Ajith TA, Jayakumar TG (2019) Omega-3 fatty acids in coronary heart disease: recent updates and future perspectives. Clin Exp Pharmacol Physiol 46(1):11–18.  https://doi.org/10.1111/1440-1681.13034CrossRefPubMedGoogle Scholar
  3. 3.
    Akagi D, Chen M, Toy R, Chatterjee A, Conte MS (2015) Systemic delivery of proresolving lipid mediators resolvin D2 and maresin 1 attenuates intimal hyperplasia in mice. FASEB J 29(6):2504–2513.  https://doi.org/10.1096/fj.14-265363CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Bennett MR, Sinha S, Owens GK (2016) Vascular smooth muscle cells in atherosclerosis. Circ Res 118(4):692–702.  https://doi.org/10.1161/CIRCRESAHA.115.306361CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Breslow JL (2006) N−3 fatty acids and cardiovascular disease. Am J Clin Nutr 83(6):1477S–1482S.  https://doi.org/10.1093/ajcn/83.6.1477SCrossRefPubMedGoogle Scholar
  6. 6.
    Calabrò P, Golia E, Maddaloni V, Malvezzi M, Casillo B, Marotta C, Golino P (2009) Adipose tissue-mediated inflammation: the missing link between obesity and cardiovascular disease? Intern Emerg Med 4(1):25–34.  https://doi.org/10.1007/s11739-008-0207-2CrossRefPubMedGoogle Scholar
  7. 7.
    Calder PC, Grimble RF (2002) Polyunsaturated fatty acids, inflammation and immunity. Eur J Clin Nutr 56(Suppl 3):S14–S19.  https://doi.org/10.1038/sj.ejcn.1601478CrossRefPubMedGoogle Scholar
  8. 8.
    Capó X, Martorell M, Busquets-Cortés C, Tejada S, Tur JA, Pons A, Sureda A (2018) Resolvins as proresolving inflammatory mediators in cardiovascular disease. Eur J Med Chem 153:123–130.  https://doi.org/10.1016/j.ejmech.2017.07.018CrossRefPubMedGoogle Scholar
  9. 9.
    Chatterjee A, Komshian S, Sansbury BE, Wu B, Mottola G, Chen M, Conte MS (2017) Biosynthesis of proresolving lipid mediators by vascular cells and tissues. FASEB J 31(8):3393–3402.  https://doi.org/10.1096/fj.201700082RCrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Chin BSP, Blann AD, Gibbs CR, Chung NAY, Conway DG, Lip GYH (2003) Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. Eur J Clin Investig 33(11):941–948CrossRefGoogle Scholar
  11. 11.
    Dalli J, Colas RA, Serhan CN (2013) Novel n-3 Immunoresolvents: structures and actions. Sci Rep 3(1):1940.  https://doi.org/10.1038/srep01940CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Dalli J, Serhan CN (2012) Specific lipid mediator signatures of human phagocytes: microparticles stimulate macrophage efferocytosis and pro-resolving mediators. Blood 120(15):e60–e72.  https://doi.org/10.1182/blood-2012-04-423525CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Das UN (2008) Can endogenous lipid molecules serve as predictors and prognostic markers of coronary heart disease? Lipids Health Dis 7(1):19.  https://doi.org/10.1186/1476-511X-7-19CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    de Goede J, Geleijnse JM, Boer JMA, Kromhout D, Verschuren WMM (2010) Marine (n-3) fatty acids, fish consumption, and the 10-year risk of fatal and nonfatal coronary heart disease in a large population of Dutch adults with low fish intake. J Nutr 140(5):1023–1028.  https://doi.org/10.3945/jn.109.119271CrossRefPubMedGoogle Scholar
  15. 15.
    Drechsler M, de Jong R, Rossaint J, Viola JR, Leoni G, Wang JM et al (2015) Annexin A1 counteracts chemokine-induced arterial myeloid cell recruitment. Circ Res 116(5):827–835.  https://doi.org/10.1161/CIRCRESAHA.116.305825CrossRefPubMedGoogle Scholar
  16. 16.
    Elajami TK, Colas RA, Dalli J, Chiang N, Serhan CN, Welty FK (2016) Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling. FASEB J 30(8):2792–2801.  https://doi.org/10.1096/fj.201500155RCrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Frantz S, Nahrendorf M (2014) Cardiac macrophages and their role in ischaemic heart disease. Cardiovasc Res 102(2):240–248.  https://doi.org/10.1093/cvr/cvu025CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Fredman G, Hellmann J, Proto JD, Kuriakose G, Colas RA, Dorweiler B et al (2016) An imbalance between specialized pro-resolving lipid mediators and pro-inflammatory leukotrienes promotes instability of atherosclerotic plaques. Nat Commun 7(1):12859.  https://doi.org/10.1038/ncomms12859CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Fredman G, Spite M (2017) Specialized pro-resolving mediators in cardiovascular diseases. Mol Asp Med 58:65–71.  https://doi.org/10.1016/j.mam.2017.02.003CrossRefGoogle Scholar
  20. 20.
    Fredman G, Van Dyke TE, Serhan CN (2010) Resolvin E1 regulates adenosine diphosphate activation of human platelets. Arterioscler Thromb Vasc Biol 30(10):2005–2013.  https://doi.org/10.1161/ATVBAHA.110.209908CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Frostegård J (2013) Immunity, atherosclerosis and cardiovascular disease. BMC Med 11(1):117.  https://doi.org/10.1186/1741-7015-11-117CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Fujiu K, Nagai R (2013) Contributions of cardiomyocyte–cardiac fibroblast–immune cell interactions in heart failure development. Basic Res Cardiol 108(4):357.  https://doi.org/10.1007/s00395-013-0357-xCrossRefPubMedGoogle Scholar
  23. 23.
    Gilbert K, Bernier J, Bourque-Riel V, Malick M, Rousseau G (2015) Resolvin D1 reduces infarct size through a phosphoinositide 3-kinase/protein kinase B mechanism. J Cardiovasc Pharmacol 66(1):72–79.  https://doi.org/10.1097/FJC.0000000000000245CrossRefPubMedGoogle Scholar
  24. 24.
    Gong Y, Lin M, Piao L, Li X, Yang F, Zhang J et al (2015) Aspirin enhances protective effect of fish oil against thrombosis and injury-induced vascular remodelling. Br J Pharmacol 172(23):5647–5660.  https://doi.org/10.1111/bph.12986CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    González-Pacheco H, Bojalil R, Amezcua-Guerra LM, Sandoval J, Eid-Lidt G, Arias-Mendoza A, Martínez-Sánchez C (2019) Derivation and validation of a simple inflammation-based risk score system for predicting in-hospital mortality in acute coronary syndrome patients. J Cardiol 73(5):416–424.  https://doi.org/10.1016/j.jjcc.2018.11.010CrossRefPubMedGoogle Scholar
  26. 26.
    Hameed I, Masoodi SR, Mir SA, Nabi M, Ghazanfar K, Ganai BA (2015) Type 2 diabetes mellitus: from a metabolic disorder to an inflammatory condition. World J Diabetes 6(4):598–612.  https://doi.org/10.4239/wjd.v6.i4.598CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Hasturk H, Abdallah R, Kantarci A, Nguyen D, Giordano N, Hamilton J, Van Dyke TE (2015) Resolvin E1 (RvE1) attenuates atherosclerotic plaque formation in diet and inflammation-induced Atherogenesis. Arterioscler Thromb Vasc Biol 35(5):1123–1133.  https://doi.org/10.1161/ATVBAHA.115.305324CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Heidt T, Courties G, Dutta P, Sager HB, Sebas M, Iwamoto Y et al (2014) Differential contribution of monocytes to heart macrophages in steady-state and after myocardial infarction. Circ Res 115(2):284–295.  https://doi.org/10.1161/CIRCRESAHA.115.303567CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Ji R-R, Xu Z-Z, Strichartz G, Serhan CN (2011) Emerging roles of resolvins in the resolution of inflammation and pain. Trends Neurosci 34(11):599–609.  https://doi.org/10.1016/j.tins.2011.08.005CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Kain V, Ingle KA, Colas RA, Dalli J, Prabhu SD, Serhan CN et al (2015) Resolvin D1 activates the inflammation resolving response at splenic and ventricular site following myocardial infarction leading to improved ventricular function. J Mol Cell Cardiol 84:24–35.  https://doi.org/10.1016/j.yjmcc.2015.04.003CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Keyes KT, Ye Y, Lin Y, Zhang C, Perez-Polo JR, Gjorstrup P, Birnbaum Y (2010) Resolvin E1 protects the rat heart against reperfusion injury. Am J Phys Heart Circ Phys 299(1):H153–H164.  https://doi.org/10.1152/ajpheart.01057.2009CrossRefGoogle Scholar
  32. 32.
    Kumar A, Mastana SS, Lindley MR (2016) n-3 fatty acids and asthma. Nutr Res Rev 29(01):1–16.  https://doi.org/10.1017/S0954422415000116CrossRefPubMedGoogle Scholar
  33. 33.
    Lee CH (2012) Resolvins as new fascinating drug candidates for inflammatory diseases. Arch Pharm Res 35(1):3–7.  https://doi.org/10.1007/s12272-012-0121-zCrossRefPubMedGoogle Scholar
  34. 34.
    Leslie CC (2015) Cytosolic phospholipase a 2 : physiological function and role in disease. J Lipid Res 56(8):1386–1402.  https://doi.org/10.1194/jlr.R057588CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Lordan S, Ross RP, Stanton C (2011) Marine bioactives as functional food ingredients: potential to reduce the incidence of chronic diseases. Mar Drugs 9(6):1056–1100.  https://doi.org/10.3390/md9061056CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Marik PE, Varon J (2009) Omega-3 dietary supplements and the risk of cardiovascular events: a systematic review. Clin Cardiol 32(7):365–372.  https://doi.org/10.1002/clc.20604CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Martinet W, Meyer I, Verheye S, Schrijvers DM, Timmermans J-P, Meyer GRY (2013) Drug-induced macrophage autophagy in atherosclerosis: for better or worse? Basic Res Cardiol 108(1):321.  https://doi.org/10.1007/s00395-012-0321-1CrossRefPubMedGoogle Scholar
  38. 38.
    Miyahara T, Runge S, Chatterjee A, Chen M, Mottola G, Fitzgerald JM et al (2013) D-series resolvin attenuates vascular smooth muscle cell activation and neointimal hyperplasia following vascular injury. FASEB J 27(6):2220–2232.  https://doi.org/10.1096/fj.12-225615CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Morin C, Blier PU, Fortin S (2015) Eicosapentaenoic acid and docosapentaenoic acid monoglycerides are more potent than docosahexaenoic acid monoglyceride to resolve inflammation in a rheumatoid arthritis model. Arthritis Res Ther 17(1):142.  https://doi.org/10.1186/s13075-015-0653-yCrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Mozaffarian D, Lemaitre RN, King IB, Song X, Spiegelman D, Sacks FM et al (2011) Circulating long-chain ω-3 fatty acids and incidence of congestive heart failure in older adults: the cardiovascular health study. Ann Intern Med 155(3):160–170.  https://doi.org/10.7326/0003-4819-155-3-201108020-00006CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Nahrendorf M, Swirski FK (2014) Imaging systemic inflammation in patients with acute myocardial infarction. Circ Cardiovasc Imaging 7(5):762–764.  https://doi.org/10.1161/CIRCIMAGING.114.002410CrossRefPubMedGoogle Scholar
  42. 42.
    Niiranen TJ, Vasan RS (2016) Epidemiology of cardiovascular disease: recent novel outlooks on risk factors and clinical approaches. Expert Rev Cardiovasc Ther 14(7):855–869.  https://doi.org/10.1080/14779072.2016.1176528CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Ouchi N, Parker JL, Lugus JJ, Walsh K (2011) Adipokines in inflammation and metabolic disease. Nat Rev Immunol 11(2):85–97.  https://doi.org/10.1038/nri2921CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Patterson AC, Chalil A, Aristizabal Henao JJ, Streit IT, Stark KD (2015) Omega-3 polyunsaturated fatty acid blood biomarkers increase linearly in men and women after tightly controlled intakes of 0.25, 0.5, and 1 g/d of EPA + DHA. Nutr Res 35(12):1040–1051.  https://doi.org/10.1016/j.nutres.2015.09.016CrossRefPubMedGoogle Scholar
  45. 45.
    Poreba M, Mostowik M, Siniarski A, Golebiowska-Wiatrak R, Malinowski KP, Haberka M, Gajos G (2017) Treatment with high-dose n-3 PUFAs has no effect on platelet function, coagulation, metabolic status or inflammation in patients with atherosclerosis and type 2 diabetes. Cardiovasc Diabetol 16(1):50.  https://doi.org/10.1186/s12933-017-0523-9CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Roifman I, Beck PL, Anderson TJ, Eisenberg MJ, Genest J (2011) Chronic inflammatory diseases and cardiovascular risk: a systematic review. Can J Cardiol 27(2):174–182.  https://doi.org/10.1016/j.cjca.2010.12.040CrossRefPubMedGoogle Scholar
  47. 47.
    Salic K, Morrison MC, Verschuren L, Wielinga PY, Wu L, Kleemann R et al (2016) Resolvin E1 attenuates atherosclerosis in absence of cholesterol-lowering effects and on top of atorvastatin. Atherosclerosis 250:158–165.  https://doi.org/10.1016/j.atherosclerosis.2016.05.001CrossRefPubMedGoogle Scholar
  48. 48.
    Schwanke RC, Marcon R, Bento AF, Calixto JB (2016) EPA- and DHA-derived resolvins’ actions in inflammatory bowel disease. Eur J Pharmacol 785:156–164.  https://doi.org/10.1016/j.ejphar.2015.08.050CrossRefPubMedGoogle Scholar
  49. 49.
    Serhan CN (2014) Pro-resolving lipid mediators are leads for resolution physiology. Nature 510(7503):92–101.  https://doi.org/10.1038/nature13479CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Serhan CN, Chiang N, Dalli J (2015) The resolution code of acute inflammation: novel pro-resolving lipid mediators in resolution. Semin Immunol 27(3):200–215.  https://doi.org/10.1016/j.smim.2015.03.004CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Serhan CN, Chiang N, Van Dyke TE (2008) Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8(5):349–361.  https://doi.org/10.1038/nri2294CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Shaikh NA, Yantha J, Shaikh S, Rowe W, Laidlaw M, Cockerline C et al (2014) Efficacy of a unique omega-3 formulation on the correction of nutritional deficiency and its effects on cardiovascular disease risk factors in a randomized controlled VASCAZEN® REVEAL trial. Mol Cell Biochem 396(1–2):9–22.  https://doi.org/10.1007/s11010-014-2132-1CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Shi Y, Pan H, Zhang H-Z, Zhao X-Y, Jin J, Wang H-Y (2017) Lipoxin A4 mitigates experimental autoimmune myocarditis by regulating inflammatory response, NF-κB and PI3K/Akt signaling pathway in mice. Eur Rev Med Pharmacol Sci 21(8):1850–1859PubMedGoogle Scholar
  54. 54.
    Sica A, Mantovani A (2012) Macrophage plasticity and polarization: in vivo veritas. J Clin Investig 122(3):787–795.  https://doi.org/10.1172/JCI59643CrossRefPubMedGoogle Scholar
  55. 55.
    Simopoulos AP (2008) The importance of the Omega-6/Omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases. Exp Biol Med 233(6):674–688.  https://doi.org/10.3181/0711-MR-311CrossRefGoogle Scholar
  56. 56.
    Swirski FK, Nahrendorf M (2013) Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 339(6116):161–166.  https://doi.org/10.1126/science.1230719CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Virmani R, Burke AP, Farb A, Kolodgie FD (2006) Pathology of the vulnerable plaque. J Am Coll Cardiol 47(8):C13–C18.  https://doi.org/10.1016/j.jacc.2005.10.065CrossRefPubMedGoogle Scholar
  58. 58.
    Wang A, Luan HH, Medzhitov R (2019) An evolutionary perspective on immunometabolism. Science 363(6423):eaar3932.  https://doi.org/10.1126/science.aar3932CrossRefPubMedGoogle Scholar
  59. 59.
    Wu B, Mottola G, Chatterjee A, Lance KD, Chen M, Siguenza IO et al (2017) Perivascular delivery of resolvin D1 inhibits neointimal hyperplasia in a rat model of arterial injury. J Vasc Surg 65(1):207–217.e3.  https://doi.org/10.1016/j.jvs.2016.01.030CrossRefPubMedGoogle Scholar
  60. 60.
    Yadav NS, Wierzbicki A, Aegerter M, Caster CS, Pérez-Grau L, Kinney AJ et al (1993) Cloning of higher plant omega-3 fatty acid desaturases. Plant Physiol 103(2):467–476CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • M. Brianza-Padilla
    • 1
  • R. Bojalil
    • 2
  1. 1.Department of ImmunologyInstituto Nacional de Cardiología Ignacio ChávezMexico CityMexico
  2. 2.Department of Health CareUniversidad Autónoma Metropolitana-XochimilcoMexico CityMexico

Personalised recommendations